Group 1 - The company announced a change in its supervisory board, specifically that Dong Boyang will no longer serve as a supervisor [1] - The decision was made by the company's shareholder, Guotai Junan Securities Co., Ltd., in accordance with the company's articles of association [1] - The announcement was officially made on October 14, 2025 [1]

Core Insights - The article emphasizes the strategic importance of Shanghai in the global economic landscape, particularly in the context of offshore financial center development and the acceleration of RMB internationalization [2][4]. Group 1: Offshore Financial Center Development - The article discusses the collaborative efforts of various institutions, including regulatory bodies, academia, and industry, to address the challenges of building an offshore financial center in Shanghai [4]. - It highlights the need for theoretical analysis, international benchmarking, policy design discussions, and practical exploration to overcome development bottlenecks and unleash institutional innovation dividends [4]. Group 2: Event Overview - The event includes a series of discussions featuring prominent speakers from regulatory, academic, and practical perspectives, focusing on strategic thoughts, theoretical logic, current status, and international experiences related to offshore financial centers [5]. - Key topics include regulatory perspectives on Shanghai's offshore financial center strategy, theoretical insights into offshore financial centers, policy research on current development and investment opportunities, and practical analysis from banking perspectives [5].

Core Insights - He Yuan Bio has developed an innovative technology called "rice blood production" over nearly 20 years, focusing on rice endosperm cell bioreactor technology, which has led to the establishment of efficient recombinant protein expression and purification platforms [2] - The company's core product, recombinant human albumin injection (from rice), was approved for market release in July this year, marking a significant shift from reliance on plasma extraction for such products [2] - He Yuan Bio has secured over 80 invention patents and built an intelligent production line capable of producing 10 tons of raw liquid and 1 million dosage forms annually, establishing a sales network across more than 30 provinces and cities in China [2] - The company is set to begin construction of a new industrial base project in September 2024, which will have an annual production capacity of 120 tons of raw liquid, enhancing its competitive edge in the recombinant human albumin market [2] Industry Context - He Yuan Bio is the first company to pass the review under the fifth set of standards of the Sci-Tech Innovation Board after its restart, highlighting the capital market's support for technological innovation and its adaptability to high-quality tech enterprises [3] - The successful listing of He Yuan Bio on the capital market represents a milestone in its development, indicating the company's entry into a new phase with unlimited potential [3] - The underwriting and sponsorship by Guotai Junan Securities emphasizes the commitment to providing professional services in the capital market, ensuring compliance with relevant regulations during the IPO process [4]

中国稀土今日涨停，成交额68.13亿元，换手率11.02%，盘后龙虎榜数据显示，深股通专用席位买入 1.62亿元并卖出1.98亿元，有1家机构专用席位净卖出7728.97万元。国泰海通证券北京国贸营业部席位 净买入5.12亿元。 ...

转自：智通财经 【龙虎榜|中国稀土今日涨停 国泰海通证券北京国贸营业部席位净买入5.12亿元】智通财经10月13日 电，中国稀土今日涨停，成交额68.13亿元，换手率11.02%，盘后龙虎榜数据显示，深股通专用席位买 入1.62亿元并卖出1.98亿元，有1家机构专用席位净卖出7728.97万元。国泰海通证券北京国贸营业部席 位净买入5.12亿元。 ...

每经AI快讯，10月13日，中国稀土（000831）涨停，成交额68.13亿元，换手率11.02%，盘后龙虎榜数 据显示，深股通专用席位买入1.62亿元并卖出1.98亿元，有1家机构专用席位净卖出7728.97万元。国泰 海通证券北京国贸营业部席位净买入5.12亿元。 ...

中国稀土今日涨停，成交额68.13亿元，换手率11.02%。盘后龙虎榜数据显示，深股通专用席位买入1.62亿元并卖出1.98亿元，有1家机构专用席位净卖出 7728.97万元。国泰海通证券北京国贸营业部席位净买入5.12亿元。 | 公告日期 2025-10-13 | 异常期间 无 | | | | | --- | --- | --- | --- | --- | | 中国稀土 (000831) | 成交量 | 116,924,284 份/股 | 成交金额 | 6,813,013,176 元 | | 口价格涨幅值率估计可10770% | | | | | | 买 | 会员营业部名称 | 买入金额 | 卖出金额 | | | --- | --- | --- | --- | --- | | | | (元) | (元) | | | 买1 | 国泰海通证券股份有限公司北京国贸证 券营业部 | 512,844,400 | | 691,122 | | 买2 | 深股通专用 | 161.951.766 | 197.850.323 | | | 买3 | 中国银河证券股份有限公司荆门证券营 业部 | 136.954.894 | 137, ...

证券之星消息，10月13日上海海通证券资产管理有限公司发布《海通鑫诚六个月持有期债券型集合资产 管理计划基金暂停申购、转换转入、定期定额投资公告》。公告中提示，为保证集合资产管理计划的平 稳运作，保护集合资产管理计划持有人利益，自2025年10月13日起海通鑫诚六个月持有期债券型集合资 产管理计划基金暂停申购、转换转入、定期定额投资，下属分级基金调整明细如下： | 分级基金简称 | 代码 | 是否暂停（大额）申购 | 申购限额 转入限额 定投限额 | | --- | --- | --- | --- | | | | (转入转出、赎回、定投) | (元) (元) (元) | | 海通臻成六个 月持有A | 852089 | 분 | | | 海通臻诚六个 月持有C | 852099 | 물 | | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

证券之星消息，10月13日上海海通证券资产管理有限公司发布《海通鑫逸债券型集合资产管理计划基金 暂停申购、转换转入、定期定额投资公告》。公告中提示，为保证集合资产管理计划的平稳运作，保护 集合资产管理计划持有人利益，自2025年10月13日起海通鑫逸债券型集合资产管理计划基金暂停申购、 转换转入、定期定额投资，下属分级基金调整明细如下： | 分级基金简称 代码 | | 是否暂停（大额）申购 | 申购限额 转入限额 定投限额 | | | --- | --- | --- | --- | --- | | | | (转入转出、赎回、定投) | (元) (元) | (元) | | 海通葵逸A | 851860 | 를 | | | | 851880 海通壁逸C | | 를 | | | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

证券之星消息，10月13日上海海通证券资产管理有限公司发布《海通品质升级一年持有期混合型集合资 产管理计划基金暂停申购、转换转入、定期定额投资公告》。公告中提示，None，自2025年10月13日 起海通品质升级一年持有期混合型集合资产管理计划基金暂停申购、转换转入、定期定额投资，下属分 级基金调整明细如下： | 分级基金简称 | 代码 | 是否暂停（大额）申购 | 申购限额 转入限额 定投限额 | | --- | --- | --- | --- | | | | (转入转出、赎回、定投) | (元) (元) (元) | | 海浦品质升级A 850013 | | 否 | | | 海通局后升级C 851399 | | 合 | | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...